Surrogate Markers for Cardiovascular Disease: Functional Markers

The endothelium constitutes the largest organ system in the body. “Endothelial function” refers to a multitude of physiological functions of the vascular endothelium that are achieved via secretion of diverse bioactive substances. This renders the endothelium an active participant in healthy homeostasis of the vascular wall that includes normal vasomotion, inhibition of platelet aggregation and thrombus generation, and maintenance of relative impermeability. Cardiovascular risk factors activate a number of pro-oxidative genes in the vascular wall resulting in generation of reactive oxygen species that ultimately promote endothelial release of transcriptional and growth factors, proinflammatory cytokines, chemoattractant substances, and adhesion molecules.1–3 This complex cascade of events underlies the transition from normal endothelial function to endothelial dysfunction. One of the earliest manifestations of increased vascular oxidant stress is the reduced bioavailability of nitric oxide (NO) as a result of inhibition and uncoupling of endothelial NO synthase, the enzyme responsible for generation of NO, and from rapid catabolism of available NO by reactive oxygen species to peroxynitrite and hydrogen peroxide that can further amplify vascular oxidative stress. The resulting functional consequences include abnormal vasomotor activity, development of a procoagulant endothelial surface, inflammation, and, ultimately, plaque formation. Clinical measurements of endothelium-dependent vasodilation (NO-mediated process) by a variety of different techniques provide a marker of endothelial integrity. Almost all conventional risk factors for atherosclerosis are associated with endothelial dysfunction. These include sedentary lifestyle and obesity, hypercholesterolemia, hypertension, diabetes, insulin resistance, smoking, and aging. The extent of endothelial dysfunction appears to correlate with the traditional risk factor “burden,” thus implying that combined or repeated injury to the vascular endothelium results in greater dysfunction. Nevertheless, there is considerable heterogeneity in the magnitude of dysfunction observed in individuals with similar risk factor profiles.4,5 Novel risk factors such as infections, hyperhomocystinemia, genetic heterogeneity, and the variable duration of …

[1]  A. Quyyumi,et al.  Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. , 2003, The New England journal of medicine.

[2]  J. K. Lloyd,et al.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.

[3]  S. Laurent,et al.  Aortic Stiffness Is an Independent Predictor of Primary Coronary Events in Hypertensive Patients: A Longitudinal Study , 2002, Hypertension.

[4]  K. Martin,et al.  Postmenopausal hormone-replacement therapy. , 2001, The New England journal of medicine.

[5]  E. Nabel,et al.  Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. , 1989, The Journal of clinical investigation.

[6]  L. Ramsay,et al.  Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence? , 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[7]  A. Quyyumi,et al.  Role of Endothelium‐Derived Nitric Oxide in the Abnormal Endothelium‐Dependent Vascular Relaxation of Patients With Essential Hypertension , 1993, Circulation.

[8]  J. Blacher,et al.  Central Pulse Pressure and Mortality in End-Stage Renal Disease , 2002, Hypertension.

[9]  T. Murakami,et al.  Excess of mortality in patients with endothelial dysfunction , 2003 .

[10]  H. Bazett,et al.  THE PRESSURE CHANGES INDUCED IN THE VASCULAR SYSTEM AS THE RESULT OF COMPRESSION OF A LIMB, AND THEIR EFFECT ON THE INDIRECT MEASUREMENT OF LATERAL PRESSURES , 1935 .

[11]  G. Schillaci,et al.  Prognostic significance of the white coat effect. , 1997, Hypertension.

[12]  Ayan R Patel,et al.  Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. , 2003, American heart journal.

[13]  G. B. John Mancini,et al.  Angiotensin Converting Enzyme Inhibition, with Quinapril, Improves Endothelial Vasomotor Dysfunction in Patients with Coronary Artery Disease: the TREND Study (Trial on REversing ENdothelial Dysfunction) , 1996 .

[14]  David M. Herrington,et al.  Erratum: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the international brachial artery reactivity task force (Journal of American College of Cardiology (2002) 39 (257-265)) , 2002 .

[15]  S Omata,et al.  Myocardial tactile stiffness: a variable of regional myocardial function. , 1998, Journal of the American College of Cardiology.

[16]  N. Schork,et al.  “White Coat” Versus “Sustained” Borderline Hypertension in Tecumseh, Michigan , 1990, Hypertension.

[17]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[18]  P. Lund-johansen Blood pressure response during exercise as a prognostic factor. , 2002, Journal of hypertension.

[19]  Detection The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[20]  D. Celermajer,et al.  Atherosclerosis in the human brachial artery. , 1997, Journal of the American College of Cardiology.

[21]  A. Quyyumi,et al.  Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. , 1995, The Journal of clinical investigation.

[22]  B. Lindgren,et al.  Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. , 2003, American journal of hypertension.

[23]  A. Berghold,et al.  Angiotensin receptor blockers as anti‐hypertensive treatment for patients with diabetes mellitus: meta‐analysis of controlled double‐blind randomized trials , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[24]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  W. Knowler,et al.  Effect of Proteinuria on Mortality in NIDDM , 1988, Diabetes.

[26]  A. Bank,et al.  In vivo human brachial artery elastic mechanics: effects of smooth muscle relaxation. , 1999, Circulation.

[27]  M. Criqui,et al.  Peripheral arterial disease detection, awareness, and treatment in primary care. , 2001, JAMA.

[28]  Michael T. Watkins,et al.  Predictive value of noninvasivelydetermined endothelial dysfunction for long-term cardiovascular events inpatients with peripheral vascular disease , 2003 .

[29]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.

[30]  J. Cohn,et al.  Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. , 1999, Hypertension.

[31]  L. Melton,et al.  Epidemiology of Persistent Proteinuria in Type II Diabetes Mellitus: Population-Based Study in Rochester, Minnesota , 1988, Diabetes.

[32]  D. Harrison,et al.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.

[33]  Massimo Chiariello,et al.  Endothelial Dysfunction and Cardiovascular Risk Prediction in Peripheral Arterial Disease: Additive Value of Flow-Mediated Dilation to Ankle-Brachial Pressure Index , 2003, Circulation.

[34]  Anne L. Taylor,et al.  Screening for early detection of cardiovascular disease in asymptomatic individuals. , 2003, American heart journal.

[35]  D. Levy,et al.  Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 1999, Hypertension.

[36]  P. Ganz,et al.  Estrogen Improves Endothelium-Dependent, Flow-Mediated Vasodilation in Postmenopausal Women , 1994, Annals of Internal Medicine.

[37]  L. Kuller,et al.  The first report of the Systolic and Pulse Pressure (SYPP) Working Group. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[38]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[39]  L Guize,et al.  Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. , 1997, Hypertension.

[40]  A. Quyyumi Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. , 1998, The American journal of medicine.

[41]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[42]  D. Levy,et al.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. , 1999, Circulation.

[43]  M. Schluchter,et al.  The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) , 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[44]  J. Blacher,et al.  Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. , 1999, Hypertension.

[45]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[46]  S M Finkelstein,et al.  Vascular hemodynamic impedance measurement. , 1982, Progress in cardiovascular diseases.

[47]  T. Meinertz,et al.  Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease , 2001, Circulation.

[48]  J. Cohn Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease. , 1999, Progress in cardiovascular diseases.

[49]  A P Avolio,et al.  Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. , 1985, Circulation.

[50]  J. Cohn,et al.  Noninvasive pulse wave analysis for the early detection of vascular disease. , 1995, Hypertension.

[51]  A. Ignaszewski,et al.  The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[52]  T. Lakka,et al.  Systolic Blood Pressure Response to Exercise Stress Test and Risk of Stroke , 2001, Stroke.

[53]  M. Watkins,et al.  Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. , 2003, Journal of the American College of Cardiology.

[54]  J. Cohn,et al.  Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.

[55]  N. Flavahan Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. , 1992, Circulation.

[56]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[57]  M. Noble,et al.  Left ventricular load, arterial impedance and their interrelationship. , 1979, Cardiovascular research.

[58]  M. Clement,et al.  PREVENTION AND TREATMENT , 1944 .

[59]  J. Laragh,et al.  Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial , 2001 .

[60]  G. L’italien,et al.  Distribution of blood pressure and hypertension in Canada and the United States. , 2001, American journal of hypertension.

[61]  J. Cohn,et al.  Arterial compliance abnormalities in isolated systolic hypertension. , 2001, American journal of hypertension.

[62]  National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. , 1993, Archives of internal medicine.

[63]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[64]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[65]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[66]  G. Remuzzi,et al.  Pathophysiology of progressive nephropathies. , 1998, The New England journal of medicine.

[67]  S. Higano,et al.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. , 2000, Circulation.

[68]  J. Laragh,et al.  Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. , 2001, Blood pressure.

[69]  Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. , 1971 .

[70]  P Ducimetière,et al.  Prognostic significance of exercise blood pressure and heart rate in middle-aged men. , 1992, Hypertension.

[71]  M Ishii,et al.  [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[72]  K. Kostner,et al.  Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. , 2000, The American journal of cardiology.

[73]  S M Grundy,et al.  Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Circulation.

[74]  D. Beevers,et al.  Clinical Hypertension , 2002, Journal of Human Hypertension.

[75]  Heidi D Nelson,et al.  Postmenopausal hormone replacement therapy: scientific review. , 2002, JAMA.

[76]  G. Schillaci,et al.  Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. , 1990, Circulation.

[77]  A. Demaria,et al.  Development and validation of a noninvasive method to determine arterial pressure and vascular compliance. , 1997, The American journal of cardiology.

[78]  E. Schiffrin,et al.  Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. , 2000, Circulation.

[79]  S. Pede,et al.  Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. , 1998, Hypertension.

[80]  G. McVeigh,et al.  Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. , 2001, Clinical science.

[81]  G. Viberti,et al.  Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect , 2002, Circulation.

[82]  M. Watkins,et al.  Risk Stratification for Postoperative Cardiovascular Events via Noninvasive Assessment of Endothelial Function: A Prospective Study , 2002, Circulation.

[83]  A. Heagerty,et al.  Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation--contraction coupling in isolated resistance vessels from essential hypertensives. , 1987, Circulation research.

[84]  C. Schmid,et al.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. , 2001, Annals of internal medicine.

[85]  M F O'Rourke,et al.  Pressure and flow waves in systemic arteries and the anatomical design of the arterial system. , 1967, Journal of applied physiology.

[86]  A. Hill,et al.  The Velocity of the Pulse Wave in Man , 1922 .

[87]  E. Schiffrin,et al.  Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. , 1994, Hypertension.

[88]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[89]  R D Rudolf,et al.  High Blood Pressure , 1937, Canadian Medical Association journal.

[90]  A. Quyyumi,et al.  Aspirin improves endothelial dysfunction in atherosclerosis. , 1998, Circulation.

[91]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[92]  J. Cohn,et al.  First- and third-order models for determining arterial compliance. , 1992, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[93]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[94]  J. Hansen,et al.  Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. , 1994, European heart journal.

[95]  K Rodahl,et al.  Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. , 1993, The New England journal of medicine.

[96]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[97]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[98]  I. Meredith,et al.  Comparison of generalized and gender-specific transfer functions for the derivation of aortic waveforms. , 2002, American journal of physiology. Heart and circulatory physiology.

[99]  M. Schroll,et al.  Urinary albumin excretion. An independent predictor of ischemic heart disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[100]  A. Quyyumi,et al.  Prognostic Value of Coronary Vascular Endothelial Dysfunction , 2002, Circulation.

[101]  B L Langille,et al.  Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. , 1986, Science.

[102]  P. Palatini,et al.  Interactive action of the white-coat effect and the blood pressure levels on cardiovascular complications in hypertension. , 1997, The American journal of medicine.

[103]  K. Bailey,et al.  Detection and Control of High Blood Pressure in the Community , 1999 .

[104]  A. Bank,et al.  Contribution of collagen, elastin, and smooth muscle to in vivo human brachial artery wall stress and elastic modulus. , 1996, Circulation.

[105]  G. Rosano,et al.  Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels. , 2002, The American journal of cardiology.

[106]  J. Laragh,et al.  The VALUE Trial , 2005 .

[107]  M. Mulvany Remodeling of resistance vessel structure in essential hypertension. , 1993, Current opinion in nephrology and hypertension.

[108]  E. Vartiainen,et al.  Importance of Risk Factor Clustering in Coronary Heart Disease Mortality and Incidence in Eastern Finland , 1995, Journal of cardiovascular risk.

[109]  G. Levine,et al.  Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. , 1996, Circulation.

[110]  J. Liao,et al.  Effective diffusion distance of nitric oxide in the microcirculation. , 1998, The American journal of physiology.

[111]  J. Manson,et al.  Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. , 1997, Circulation.

[112]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[113]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[114]  Simon R Redwood,et al.  Pressure Wave Reflection Assessed From the Peripheral Pulse: Is a Transfer Function Necessary? , 2003, Hypertension.

[115]  S. Julius,et al.  Stroke volume--pulse pressure relationships in borderline hypertension: a possible indicator of decreased arterial compliance. , 1984, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[116]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[117]  Amir Lerman,et al.  Coronary Endothelial Dysfunction Is Associated With an Increased Risk of Cerebrovascular Events , 2003, Circulation.

[118]  J. M. Macleod,et al.  Albumin excretion and vascular deaths in NIDDM , 1995, Diabetologia.

[119]  Naguib Hilmy Postmenopausal hormone-replacement therapy. , 2002, The New England journal of medicine.

[120]  A. Fitzgerald,et al.  Prospective Study of Microalbuminuria as Predictor of Mortality in NIDDM , 1992, Diabetes.

[121]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[122]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[123]  T. Baron Badanie Valsartan Antihypertensive Long-term Use Evaluation (VALUE) , 2005 .

[124]  C. Mogensen,et al.  Eight to nine year mortality in known non-insulin dependent diabetics and controls. , 1992, Kidney international.

[125]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[126]  A. Maisel,et al.  B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. , 2001, Journal of cardiac failure.

[127]  D. Levy,et al.  Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. , 1997, Circulation.

[128]  M. Weber,et al.  Diagnosis of mild hypertension by ambulatory blood pressure monitoring. , 1994, Circulation.

[129]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[130]  W. Kannel,et al.  Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. , 1971, The American journal of cardiology.

[131]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[132]  R. Kirkpatrick,et al.  Ambulatory Blood Pressure Monitoring , 1993, The Journal of the American Board of Family Medicine.

[133]  Anders Ahlbom,et al.  Introduction to modern epidemiology , 1984 .

[134]  D. Tanné,et al.  Risk profile and prediction of long-term ischemic stroke mortality: a 21-year follow-up in the Israeli Ischemic Heart Disease (IIHD) Project. , 1998, Circulation.

[135]  G. Reboldi,et al.  Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. , 1994, Hypertension.

[136]  T. Murakami,et al.  Clinical Morbidities in Subjects With Doppler-evaluated Endothelial Dysfunction of Coronary Artery , 1998 .

[137]  H. Drexler,et al.  Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. , 1989, Journal of the American College of Cardiology.

[138]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[139]  W. Kannel Blood pressure as a cardiovascular risk factor: prevention and treatment. , 1996, JAMA.

[140]  P. Palatini,et al.  Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. , 1992, Archives of internal medicine.

[141]  E. Benjamin,et al.  Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.

[142]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[143]  A P Avolio,et al.  Pressure wave propagation in a multibranched model of the human upper limb. , 1995, The American journal of physiology.

[144]  A. Neil,et al.  A Prospective Population-Based Study of Microalbuminuria as a Predictor of Mortality in NIDDM , 1993, Diabetes Care.

[145]  K. Smith,et al.  Abnormal Coronary Vasomotion as a Prognostic Indicator of Cardiovascular Events in Women: Results From the National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE) , 2004, Circulation.

[146]  M. O'Rourke,et al.  Wave reflection in the systemic circulation and its implications in ventricular function. , 1993, Journal of hypertension.

[147]  Kdoqi Disclaimer K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[148]  T. Lüscher,et al.  Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. , 1996, Circulation.

[149]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[150]  V. Dzau Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. , 2001, Hypertension.

[151]  Y. Tardy,et al.  Conduit artery compliance and distensibility are not necessarily reduced in hypertension. , 1992, Hypertension.

[152]  W. White,et al.  Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension. , 1989, JAMA.

[153]  M. Pfisterer,et al.  Prognostic Value of Abnormal Vasoreactivity of Epicardial Coronary Arteries to Sympathetic Stimulation in Patients With Normal Coronary Angiograms , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[154]  C. Mogensen,et al.  Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. , 1984, The New England journal of medicine.

[155]  Philip Greenland,et al.  Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations , 1999 .

[156]  Majid Ezzati,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[157]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[158]  M. Laakso,et al.  Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. , 1996, Stroke.

[159]  S. Verma,et al.  Endothelial function testing as a biomarker of vascular disease. , 2003, Circulation.

[160]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[161]  Daniel Duprez,et al.  The prognostic value of ambulatory blood pressure in treated hypertension: the office versus ambulatory (OvA) blood pressure study , 2002 .

[162]  M. Sugimachi,et al.  Effect of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and forearm vasculatures in humans. , 1994, Journal of the American College of Cardiology.

[163]  A. Yeung,et al.  Close relation of endothelial function in the human coronary and peripheral circulations. , 1995, Journal of the American College of Cardiology.

[164]  F. Coppi,et al.  Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. , 2002, Journal of the American College of Cardiology.

[165]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[166]  J. Cohn Arteries, myocardium, blood pressure and cardiovascular risk: towards a revised definition of hypertension. , 1998, Journal of hypertension.

[167]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[168]  E. Nabel,et al.  Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. , 1988, Circulation.

[169]  F. Perticone,et al.  Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients , 2001, Circulation.

[170]  S S Franklin,et al.  Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. , 1999, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.